Search

Your search keyword '"Jonas B. Raedler"' showing total 5 results
Start Over Author "Jonas B. Raedler" Search Limiters Peer Reviewed
5 results on '"Jonas B. Raedler"'

1. Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas

Author

Jan H. Müller, Henning Plage, Sefer Elezkurtaj, Tim Mandelkow, Zhihao Huang, Magalie C. J. Lurati, Jonas B. Raedler, Nicolaus F. Debatin, Eik Vettorazzi, Henrik Samtleben, Sebastian Hofbauer, Kira Furlano, Jörg Neymeyer, Irena Goranova, Bernhard Ralla, Sarah Weinberger, David Horst, Florian Roßner, Simon Schallenberg, Andreas H. Marx, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek, Thorsten Ecke, Steffen Hallmann, Stefan Koch, Nico Adamini, Maximilian Lennartz, Sarah Minner, Ronald Simon, Guido Sauter, Henrik Zecha, Thorsten Schlomm, and Elena Bady

Subjects
TROP2, EpCAM, muscle invasive urothelial cancer, multiplex fluorescence immunohistochemistry, bladder cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

IntroductionTrophoblast cell surface antigen 2 (TROP2; EpCAM2) is a transmembrane glycoprotein which is closely related to EpCAM (EpCAM; EpCAM1). Both proteins share partial overlapping functions in epithelial development and EpCAM expression but have not been comparatively analyzed together in bladder carcinomas. TROP2 constitutes the target for the antibody-drug conjugate Sacituzumab govitecan (SG; TrodelvyTM) which has been approved for treatment of metastatic urothelial carcinoma by the United States Food and Drug administration (FDA) irrespective of its TROP2 expression status. MethodsTo evaluate the potential clinical significance of subtle differences in TROP2 and EpCAM expression in urothelial bladder cancer, both proteins were analyzed by multiplex fluorescence immunohistochemistry in combination with a deep-learning based algorithm for automated cell detection on more than 2,700 urothelial bladder carcinomas in a tissue microarray (TMA) format. ResultsThe staining pattern of TROP2 and EpCAM were highly similar. For both proteins, the staining intensity gradually decreased from pTa G2 low grade (TROP2: 68.8±36.1; EpCAM: 21.5±11.7) to pTa G2 high grade (64.6±38.0; 19.3±12.2) and pTa G3 (52.1±38.7; 16.0±13.0, p

Published
2024
Full Text
View/download PDF

2. Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry

Author

Tim Mandelkow, Elena Bady, Magalie C. J. Lurati, Jonas B. Raedler, Jan H. Müller, Zhihao Huang, Eik Vettorazzi, Maximilian Lennartz, Till S. Clauditz, Patrick Lebok, Lisa Steinhilper, Linn Woelber, Guido Sauter, Enikö Berkes, Simon Bühler, Peter Paluchowski, Uwe Heilenkötter, Volkmar Müller, Barbara Schmalfeldt, Albert von der Assen, Frank Jacobsen, Till Krech, Rainer H. Krech, Ronald Simon, Christian Bernreuther, Stefan Steurer, Eike Burandt, and Niclas C. Blessin

Subjects
breast cancer, prognosis markers, multiplex fluorescence immunohistochemistry, artificial intelligence, Biology (General), QH301-705.5
Abstract

Prognostic markers in routine clinical management of breast cancer are often assessed using RNA-based multi-gene panels that depend on fluctuating tumor purity. Multiplex fluorescence immunohistochemistry (mfIHC) holds the potential for an improved risk assessment. To enable automated prognosis marker detection (i.e., progesterone receptor [PR], estrogen receptor [ER], androgen receptor [AR], GATA3, TROP2, HER2, PD-L1, Ki67, TOP2A), a framework for automated breast cancer identification was developed and validated involving thirteen different artificial intelligence analysis steps and an algorithm for cell distance analysis using 11+1-marker-BLEACH&STAIN-mfIHC staining in 1404 invasive breast cancers of no special type (NST). The framework for automated breast cancer detection discriminated normal glands from malignant glands with an accuracy of 98.4%. This approach identified that five (PR, ER, AR, GATA3, PD-L1) of nine biomarkers were associated with prolonged overall survival (p ≤ 0.0095 each) and two of these (PR, AR) were found to be independent risk factors in multivariate analysis (p ≤ 0.0151 each). The combined assessment of PR-ER-AR-GATA3-PD-L1 as a five-marker prognosis score showed strong prognostic relevance (p < 0.0001) and was an independent risk factor in multivariate analysis (p = 0.0034). Automated breast cancer detection in combination with an artificial intelligence-based analysis of mfIHC enables a rapid and reliable analysis of multiple prognostic parameters. The strict limitation of the analysis to malignant cells excludes the impact of fluctuating tumor purity on assay precision.

Published
2023
Full Text
View/download PDF

3. Automated <scp>Ki</scp> ‐67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry

Author

Niclas C Blessin, Cheng Yang, Tim Mandelkow, Jonas B Raedler, Wenchao Li, Elena Bady, Ronald Simon, Eik Vettorazzi, Maximilian Lennartz, Christian Bernreuther, Christoph Fraune, Frank Jacobsen, Till Krech, Andreas Marx, Patrick Lebok, Sarah Minner, Eike Burandt, Till S Clauditz, Waldemar Wilczak, Guido Sauter, Hans Heinzer, Alexander Haese, Thorsten Schlomm, Markus Graefen, and Stefan Steurer

Subjects
Pathology and Forensic Medicine
Published
2023
Full Text
View/download PDF

4. Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers

Author

Anne Menz, Jonas B Raedler, Franziska Büscheck, Cheng Yang, Wenchao Li, Andreas Marx, Waldemar Wilczak, Katharina Möller, Guido Sauter, Stefan Steurer, Christian Bernreuther, Eike Burandt, Christoph Fraune, David Dum, Sarah Minner, Ronald Simon, Hannah L Jansen, Patrick Lebok, Niclas C Blessin, Andreas M. Luebke, Till Krech, Doris Höflmayer, Ria Uhlig, Andrea Hinsch, Tim Mandelkow, and Till S. Clauditz

Subjects
0301 basic medicine, Cancer Research, Tumor microenvironment, business.industry, Colorectal cancer, T cell, Cancer, General Medicine, medicine.disease, Immune checkpoint, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Pancreatic cancer, medicine, Cancer research, Molecular Medicine, Cytotoxic T cell, Ovarian cancer, business
Abstract

Purpose Expansion of CD8+ cytotoxic Tlymphocytes is a prerequisite for anti-cancer immune activity and has gained interest in the era of immune checkpoint therapy. Methods To understand the CD8+ T cell dynamics in the tumor microenvironment, we used multiplex fluorescence immunohistochemistry to quantitate CD8+ proliferation (Ki67 co-expression) in tissue microarrays from 1107 colorectal, 642 renal cell, 1066 breast, 375 ovarian, 451 pancreatic and 347 gastric cancer samples. Results The density and the percentage of proliferating (Ki67+) CD8+ T cells were both highly variable between tumor types as well as between patients with the same tumor type. Elevated density and percentage of proliferating CD8+ cytotoxic T cells were significantly associated with favorable tumor parameters such as low tumor stage, negative nodal stage (p ≤ 0.0041 each), prolonged overall survival (p ≤ 0.0028 each) and an inflamed immune phenotype (p = 0.0025) in colorectal cancer and, in contrast, linked to high tumor stage, advanced ISUP/Fuhrman/Thoenes grading (each p ≤ 0.003), shorter overall survival (p ≤ 0.0330 each) and an immune inflamed phenotype (p = 0.0094) in renal cell cancer. In breast, ovarian, pancreatic and gastric cancer the role of (Ki67+)CD8+ Tcells was not linked to clinicopathological data. Conclusion Our data demonstrate a tumor type dependent prognostic impact of proliferating (Ki67+)CD8+ Tcells and an inverse impact in colorectal and renal cell cancer.

Published
2021
Full Text
View/download PDF

5. Prognostic role of proliferating CD8

Author

Niclas C, Blessin, Wenchao, Li, Tim, Mandelkow, Hannah L, Jansen, Cheng, Yang, Jonas B, Raedler, Ronald, Simon, Franziska, Büscheck, David, Dum, Andreas M, Luebke, Andrea, Hinsch, Katharina, Möller, Anne, Menz, Christian, Bernreuther, Patrick, Lebok, Till, Clauditz, Guido, Sauter, Andreas, Marx, Ria, Uhlig, Waldemar, Wilczak, Sarah, Minner, Till, Krech, Christoph, Fraune, Doris, Höflmayer, Eike, Burandt, and Stefan, Steurer

Subjects
Renal cell cancer, Pancreatic cancer, CD8-Positive T-Lymphocytes, Prognosis, CD8+ cytotoxic Tcells, Immunohistochemistry, Survival Analysis, Colorectal cancer, Ki-67 Antigen, Lymphocytes, Tumor-Infiltrating, Breast cancer, Tumor microenvironment, Ovarian cancer, Neoplasms, Humans, Original Article, Lymphocyte Count, Gastric cancer, Cell Proliferation, Neoplasm Staging, T-Lymphocytes, Cytotoxic
Abstract

Purpose Expansion of CD8+ cytotoxic Tlymphocytes is a prerequisite for anti-cancer immune activity and has gained interest in the era of immune checkpoint therapy. Methods To understand the CD8+ T cell dynamics in the tumor microenvironment, we used multiplex fluorescence immunohistochemistry to quantitate CD8+ proliferation (Ki67 co-expression) in tissue microarrays from 1107 colorectal, 642 renal cell, 1066 breast, 375 ovarian, 451 pancreatic and 347 gastric cancer samples. Results The density and the percentage of proliferating (Ki67+) CD8+ T cells were both highly variable between tumor types as well as between patients with the same tumor type. Elevated density and percentage of proliferating CD8+ cytotoxic T cells were significantly associated with favorable tumor parameters such as low tumor stage, negative nodal stage (p ≤ 0.0041 each), prolonged overall survival (p ≤ 0.0028 each) and an inflamed immune phenotype (p = 0.0025) in colorectal cancer and, in contrast, linked to high tumor stage, advanced ISUP/Fuhrman/Thoenes grading (each p ≤ 0.003), shorter overall survival (p ≤ 0.0330 each) and an immune inflamed phenotype (p = 0.0094) in renal cell cancer. In breast, ovarian, pancreatic and gastric cancer the role of (Ki67+)CD8+ Tcells was not linked to clinicopathological data. Conclusion Our data demonstrate a tumor type dependent prognostic impact of proliferating (Ki67+)CD8+ Tcells and an inverse impact in colorectal and renal cell cancer. Supplementary Information The online version contains supplementary material available at 10.1007/s13402-021-00601-4.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results